AR032730A1 - Desnaturalizantes para las sales aminas simpaticomimeticas - Google Patents

Desnaturalizantes para las sales aminas simpaticomimeticas

Info

Publication number
AR032730A1
AR032730A1 ARP990104527A ARP990104527A AR032730A1 AR 032730 A1 AR032730 A1 AR 032730A1 AR P990104527 A ARP990104527 A AR P990104527A AR P990104527 A ARP990104527 A AR P990104527A AR 032730 A1 AR032730 A1 AR 032730A1
Authority
AR
Argentina
Prior art keywords
amine
hydrochloride
sorbitol
pseudoephedrine
inhibitor
Prior art date
Application number
ARP990104527A
Other languages
English (en)
Inventor
William S Bess
William Michael Nichols
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR032730A1 publication Critical patent/AR032730A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composicion farmacéutica desnaturalizada que comprende una sal ácida de una amina simpaticomimética y al menos un inhibidor de combinacion, de reaccion o de separacion que interfiere al aislamiento de dicha amina y su conversion en otros compuestos activos, sin alterar la liberacion, biodisponibilidad y dosificacion de dicha amina. El proposito es evitar el uso de estas composiciones de venta libre en la produccion de drogas ilegales, por ejemplo metanfetamina a partir de pseudoefedrina. Dicha amina puede ser clorhidrato o sulfato de pseudoefedrina, clorhidrato de efedrina o clorhidrato de fenilpropanilamina y dicho inhibidor se selecciona entre sales de metales de transicion, como cloruro, oxido sulfato y gluconato de Fe, Co, Cu, Mn, Ni o Zn y polímeros de aminas como copolímeros de metil metacrilato o butil metacrilato y dimetilaminoetil metacrilato, compuestos polihidroxilados como glicerina, sorbitol, lactitol, manitol, xilitol, maltitol y galactosa, ésteres de glicerina, de sorbitol y otros que se describen en la memoria.
ARP990104527A 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas AR032730A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9971298P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
AR032730A1 true AR032730A1 (es) 2003-11-26

Family

ID=22276270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104527A AR032730A1 (es) 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas

Country Status (22)

Country Link
US (4) US6359011B1 (es)
EP (1) EP1112089A1 (es)
JP (1) JP2002524534A (es)
KR (1) KR20010075021A (es)
CN (1) CN1201822C (es)
AR (1) AR032730A1 (es)
AU (2) AU771194B2 (es)
BR (1) BR9913575A (es)
CA (1) CA2339354A1 (es)
CO (1) CO5280050A1 (es)
CR (1) CR6106A (es)
GT (1) GT199900148A (es)
HK (1) HK1039898A1 (es)
HN (1) HN1999000156A (es)
MY (1) MY117971A (es)
NZ (1) NZ510012A (es)
PA (1) PA8481601A1 (es)
PE (1) PE20001034A1 (es)
SV (1) SV1999000148A (es)
TW (1) TW550071B (es)
UY (1) UY25702A1 (es)
WO (1) WO2000015261A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
HUP0303700A3 (en) * 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
PT1920763E (pt) * 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004045037A1 (de) * 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US9198865B2 (en) 2006-01-19 2015-12-01 Dow Global Technologies Llc Biologically active composition comprising ethylcellulose
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
US8273798B2 (en) * 2007-06-04 2012-09-25 Shear Kershman Laboratories Tamper resistant lipid-based oral dosage form for opioid agonists
CA2731801C (en) * 2007-07-23 2013-11-26 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
JP4879351B2 (ja) 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013036567A2 (en) * 2011-09-07 2013-03-14 Johnson Brent A Methods, compositions, and compounds for the reduction of illegal methamphetamine production
US20150238615A1 (en) * 2011-12-12 2015-08-27 Leonard Mackles Denaturants for sympathomimetic amines
CA2880163A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
EP3016645A4 (en) * 2013-07-03 2016-12-21 Acura Pharmaceuticals Inc PROCEDURE AND COMPOSITIONS FOR DETECTING FROM ABUSE
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CA2998259A1 (en) * 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169092A (en) 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
GB1593261A (en) 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
RO68771A2 (ro) * 1976-08-25 1980-08-15 Intreprinderea De Medicamente,Ro Unguent antipruriginos si sicativ
SU1146046A1 (ru) 1983-11-11 1985-03-23 Центральный Ордена Ленина Институт Усовершенствования Врачей Состав дл ретракции десны
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
US4657757A (en) 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
ZA904021B (en) 1989-11-24 1991-02-27 Van Der Linde Leon Slimming preparations
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
NZ267002A (en) 1993-06-04 1997-07-27 Warner Lambert Co Chewable cold/sinus relief preparation comprising antihistamine and decongestant in a carrier consisting of silicon dioxide
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
AUPM814994A0 (en) 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
US5529783A (en) 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US5626878A (en) 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
PT894010E (pt) 1996-04-10 2003-11-28 Warner Lambert Co Desnaturantes para sais de amina simpaticomimetica
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.

Also Published As

Publication number Publication date
GT199900148A (es) 2001-02-28
US20060216268A1 (en) 2006-09-28
TW550071B (en) 2003-09-01
EP1112089A1 (en) 2001-07-04
AU5915799A (en) 2000-04-03
UY25702A1 (es) 1999-11-17
AU771194B2 (en) 2004-03-18
PA8481601A1 (es) 2001-04-30
PE20001034A1 (es) 2000-10-18
CN1316911A (zh) 2001-10-10
JP2002524534A (ja) 2002-08-06
AU2004202702B2 (en) 2007-11-22
NZ510012A (en) 2002-11-26
US6359011B1 (en) 2002-03-19
MY117971A (en) 2004-08-30
SV1999000148A (es) 2000-09-11
HK1039898A1 (zh) 2002-05-17
WO2000015261A1 (en) 2000-03-23
CR6106A (es) 2003-12-05
US20050256194A1 (en) 2005-11-17
KR20010075021A (ko) 2001-08-09
CO5280050A1 (es) 2003-05-30
CN1201822C (zh) 2005-05-18
AU2004202702A1 (en) 2004-07-15
BR9913575A (pt) 2001-05-22
CA2339354A1 (en) 2000-03-23
HN1999000156A (es) 2003-08-01
US20020082304A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AR032730A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
BRPI0213425B8 (pt) composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
NO20063809L (no) Belagte minitabletter av venlaflaxin hydroklorid med forlenget virkning
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
CO6220902A2 (es) Formulacion en polvo del valganciclovir
BRPI0517574A (pt) formulação farmacêutica, método para tratar ou prevenir hipercalcemia e método para preparar formulação farmacêutica
JP2002509104A5 (es)
BRPI0111911B8 (pt) preparado aplicável por via oral compreendendo ciprofloxacina
BR9913135A (pt) Formulação oral
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
Lucas et al. Ribose cysteine protects against acetaminophen-induced hepatic and renal toxicity
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
AR056480A1 (es) Composicion de antagonistas de 5-ht1b para la depresion, la ansiedad y la cognicion
UY28111A1 (es) Nueva forma de dosificación oral de liberación inmediata
RS51659B (en) THE USE OF AGOMELATIN FOR OBTAINING MEDICINES FOR THE TREATMENT OF BIPOLAR DISORDERS

Legal Events

Date Code Title Description
FB Suspension of granting procedure